A review of cost-effectiveness studies in ovarian cancer

Cancer Control

Volumn 18, Issue 1, 2011, Pages 59-64

  Sfakianos, Gregory P ^a   Havrilesky, Laura J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; PACLITAXEL;

ARTICLE; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER SCREENING; COST EFFECTIVENESS ANALYSIS; DRUG COST; HEALTH CARE COST; HUMAN; INTERMETHOD COMPARISON; OVARY CANCER; QUALITY OF LIFE; RECURRENT CANCER; SCREENING TEST; SENSITIVITY AND SPECIFICITY;

EID: 78651496121     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327481101800109     Document Type: Article

References (53)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277-300.
2. Berek JS. Epithelial ovarian cancer. In: Berek JS, Hacker NF, eds. Practical Gynecologic Oncology. 4th ed. Chapter 11. Philadelphia, PA: Lippincott Williams & Wilkins; 2004.
3. Heintz AP, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006;95(suppl 1):S161-S192.
4. Kaiser Family Foundation. Trends in Health Care Costs and Spending. March 2009. http://www.kff.org/insurance/upload/7692_02.pdf. Accessed October 11, 2010.
5. Yabroff KR, Lamont EB, Mariotto A, et al. Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst. 2008;100(9):630-641.
6. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. June 2008. http://www.nice.org.uk/media/ B52/A7/TAMethodsGuideUpdatedJune2008.pdf. Accessed October 11, 2010.
7. Gold MR, Siegel JE, Russell LB, et al, eds. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996.
8. Brazier J, Deverill M, Green C, et al. A review of the use of health status measures in economic evaluation. Health Technol Assess. 1999;3(9): i-iv, 1-164.
9. Sun CC, Bodurka DC, Donato ML, et al. Patient preferences regarding side effects of chemotherapy for ovarian cancer: do they change over time? Gynecol Oncol. 2002;87(1):118-128.
10. Donovan KA, Greene PG, Shuster JL, et al. Treatment preferences in recurrent ovarian cancer. Gynecol Oncol. 2002;86(2):200-211.
11. Owens DK. Analytic tools for public health decision making. Med Decis Making. 2002;22(5 suppl):S3-S10.
12. Jacobs I, Bast RC Jr. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod. 1989;4(1):1-12.
13. Bell R, Petticrew M, Sheldon T. The performance of screening tests for ovarian cancer: results of a systematic review. Br J Obstet Gynaecol. 1998;105(11):1136-1147.
14. Einhorn N, Sjövall K, Knapp RC, et al. Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer. Obstet Gynecol. 1992;80(1):14-18.
15. Jacobs IJ, Skates S, Davies AP, et al. Risk of diagnosis of ovarian cancer after raised serum CA 125 concentration: a prospective cohort study. BMJ. 1996;313(7069):1355-1358.
16. Helzlsouer KJ, Bush TL, Alberg AJ, et al. Prospective study of serum CA-125 levels as markers of ovarian cancer. JAMA. 1993;269(9):1123-1126.
17. van Nagell JR Jr, DePriest PD, Reedy MB, et al. The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. Gynecol Oncol. 2000;77(3):350-356.
18. Menon U, Talaat A, Jeyarajah AR, et al. Ultrasound assessment of ovarian cancer risk in postmenopausal women with CA125 elevation. Br J Cancer. 1999;80(10):1644-1647.
19. Jacobs IJ, Skates SJ, MacDonald N, et al. Screening for ovarian cancer: a pilot randomised controlled trial. Lancet. 1999;353(9160):1207-1210.
20. Skates SJ, Singer DE. Quantifying the potential benefit of CA 125 screening for ovarian cancer. J Clin Epidemiol. 1991;44(4-5):365-380.
21. Urban N, Drescher C, Etzioni R, et al. Use of a stochastic simulation model to identify an efficient protocol for ovarian cancer screening. Control Clin Trials. 1997;18(3):251-270.
22. Havrilesky LJ, Sanders GD, Kulasingam S, et al. Reducing ovarian cancer mortality through screening: Is it possible, and can we afford it? Gynecol Oncol. 2008;111(2):179-187.
23. Partridge E, Kreimer AR, Greenlee RT, et al. Results from four rounds of ovarian cancer screening in a randomized trial. Obstet Gynecol. 2009;113(4):775-782.
24. Menon U, Gentry-Maharaj A, Hallett R, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 2009;10(4):327-340.
25. Morgan RJ, Alvarez RD, Armstrong DK, et al. NCCN Clinical Practice Guidelines in Ovarian Cancer. v.2.2009. http://www.nccn.org/professionals/ physician_gls/f_guidelines.asp
26. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334(1):1-6.
27. Piccart MJ, Bertelsen K, James K, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst. 2000;92(9):699-708.
28. Piccart MJ, Bertelsen K, Stuart G, et al. Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer. Int J Gynecol Cancer. 2003;13(suppl 2):144-148.
29. Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003;21(17):3194-3200.
30. Neijt JP, Engelholm SA, Tuxen MK, et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol. 2000;18(17):3084-3092.
31. du Bois A, Lück HJ, Meier W, et al. A randomized clinical trial of cisplatin/ paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst. 2003;95(17):1320-1329.
32. Ozols RF. Update on the management of ovarian cancer. Cancer J. 2002;8(suppl 1):S22-S30.
33. McGuire W, Neugut AI, Arikian S, et al. Analysis of the cost-effectiveness of paclitaxel as alternative combination therapy for advanced ovarian cancer. J Clin Oncol. 1997;15(2):640-645.
34. Elit LM, Gafni A, Levine MN. Economic and policy implications of adopting paclitaxel as first-line therapy for advanced ovarian cancer: an Ontario perspective. J Clin Oncol. 1997;15(2):632-639.
35. Berger K, Fischer T, Szucs TD. Cost-effectiveness analysis of paclitaxel and cisplatin versus cyclophosphamide and cisplatin as first-line therapy in advanced ovarian cancer. A European perspective. Eur J Cancer. 1998;34(12):1894-1901.
36. Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 1996;335(26):1950-1955.
37. Markman M, Bundy BN, Alberts DS, et al. Phase III trial of standarddose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001;19(4):1001-1007.
38. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354(1):34-43.
39. Bristow RE, Santillan A, Salani R, et al. Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: a cost-effectiveness analysis. Gynecol Oncol. 2007; 106(3):476-481.
40. Havrilesky LJ, Secord AA, Darcy KM, et al. Cost effectiveness of intraperitoneal compared with intravenous chemotherapy for women with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2008;26(25):4144-4150.
41. Burger RA, Brady MF, Bookman MA, et al. Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study. J Clin Oncol. 2010;28(18s):LBA1. Abstract.
42. Cohn D, Kim K, Resnick K, et al. At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A costeffectiveness analysis. Presented at the Society of Gynecologic Oncologists 41st Annual Meeting on Women's Cancer; March 14-17, 2010. San Francisco, CA. Gynecol Oncol. 2010;116(3 suppl 1):S12. Abstract 28.
43. Hensley ML. Epithelial ovarian cancer. Curr Treat Options Oncol. 2002; 3(2):131-141.
44. Rose PG, Fusco N, Fluellen L, et al. Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma. J Clin Oncol. 1998;16(4):1494-1497.
45. Dizon DS, Hensley ML, Poynor EA, et al. Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer. J Clin Oncol. 2002;20(5):1238-1247.
46. Seltzer V, Vogl S, Kaplan B. Recurrent ovarian carcinoma: retreatment utilizing combination chemotherapy including cis-diamminedichloroplatinum in patients previously responding to this agent. Gynecol Oncol. 1985;21(2):167-176.
47. Gershenson DM, Kavanagh JJ, Copeland LJ, et al. Re-treatment of patients with recurrent epithelial ovarian cancer with cisplatin-based chemotherapy. Obstet Gynecol. 1989;73(5 Pt 1):798-802.
48. Gore ME, Fryatt I, Wiltshaw E, Dawson T. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol. 1990;36(2):207-211.
49. Markman M, Rothman R, Hakes T, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol. 1991;9(3):389-393.
50. Parmar MK, Ledermann JA, Colombo N, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet. 2003;361(9375):2099-2106.
51. Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol. 2006;24(29):4699-4707.
52. Havrilesky LJ, Secord AA, Kulasingam S, et al. Management of platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis. Gynecol Oncol. 2007;107(2):211-218.
53. Rocconi RP, Case AS, Straughn JM Jr, et al. Role of chemotherapy for patients with recurrent platinum-resistant advanced epithelial ovarian cancer: a cost-effectiveness analysis. Cancer. 2006;107(3):536-543.